

Delphi study investigating the clinical use of oral selexipag to treat pulmonary arterial hypertension (PAH)

Sheryl Wu¹, Gurinderpal Doad², Christina Benninger², Michelle Cho², Richard Perry³, Daisy Bridge³, Charlotte Oswald³, Luis Val-Maranes³, Paul Strachan²

¹University of California San Diego, La Jolla, CA, USA;

²Johnson & Johnson, Titusville, NJ, USA;

³Adelphi Values PROVE, Bollington, Cheshire, UK

Background

- Prostacyclin pathway agents are foundational for the treatment of pulmonary arterial hypertension (PAH). These agents have demonstrated effects on exercise capacity, PAH hospitalization rates, and mortality.
- Oral selexipag is a selective prostacyclin receptor agonist approved for patients with PAH to delay disease progression and reduce the risk of PAH-related hospitalizations, based on a robust evidence base that has been growing since GRIPHON, the largest PAH outcomes study to date.¹⁻³
- Clinicians could benefit from guidelines with recommendations on the oral selexipag dosing and titration process and expected side effect management to optimize its clinical benefits and improve patients' experience.


Objective

To reach consensus on best-practice recommendations to enhance patient care and assist with treatment management by conducting a double-blinded Delphi panel of clinical experts with oral selexipag experience.

Methods

- The study was conducted between April and November 2023 using a double-blinded modified Delphi method (Figure 1): a structured communication method to elicit consensus from a range of opinions.
- The Delphi panel included a virtual consensus meeting that was held to discuss and revise any statements that did not reach consensus in the surveys (panel rounds 1 and 2).
- A nine-point Likert scale (from 1 [strongly disagree] to 9 [strongly agree]) was used to rate consensus.

FIGURE 1: Modified Delphi panel



Results

Panelist characteristics

- Most panelists (n=11/17) practiced in accredited pulmonary hypertension centers.
- The average number of patients with PAH that the panel were treating with oral selexipag at the time of recruitment was 36 for the physicians (n=11) and 35 for the NPs and RN (n=6).

Clinical use of oral selexipag; factors leading to:

Prescribing selexipag:

- Difficulty managing prostacyclin therapies
- Lack of access to resources necessary for parenteral formulations


Not prescribing selexipag:

- Tolerability of selexipag versus other prostacyclin therapies
- Failure of other/previous therapy

Titration of oral selexipag dose

- Panelists prescribed selexipag according to the US Food and Drug Administration label; however, they noted that dosing and titration methods should be individualized for each patient (Figure 2) to achieve their personalized dose to maximize treatment benefit.

FIGURE 2: Considerations that lead panelists to change the speed of titration



*Some panelists described severe PAH as patients with high risk or World Health Organization functional class III.

"I remind patients that they do not need to get to 1600 mcg, they just need to get to the maximum dose for them." – Quote from a panelist on managing patient expectations when started on oral selexipag

Oral selexipag maximum dose

- Panelists noted that the maximum oral selexipag dose is primarily identified by the patients' tolerability to side effects.
- Prior treatment with parenteral prostacyclin therapy affected tolerability and some panelists suggested a higher selexipag dose is achievable by these patients.

Expected side effect management

- While panelists noted that the burden and duration of expected side effects can be variable and patient-specific, Figure 3 and Figure 4 show the side effects that are more clinically burdensome (selected by the panel) and the typical time for these to resolve based on their clinical experience.

FIGURE 3: Clinically burdensome side effects selected by the panel (N=17)





FIGURE 4: Median duration of expected side effects associated with oral selexipag (N=17)



- Panelists noted that side effects often become manageable with time.
- Panelists identified methods for managing each side effect (Table 1), agreeing that this should be proactive.

TABLE 1: Expected side effect management approaches that reached consensus among the panel

Expected side effect	Management approaches
Most common side effects as agreed by the panel	
Headache	✓ Acetaminophen (Tylenol®)
Diarrhea	✓ Loperamide (Imodium®)
Occasionally occurring side effects as agreed by the panel	
Nausea	✓ Take oral selexipag with food (can mean "take with a meal" and "take with a small snack") ✓ Ondansetron (Zofran®)
Pain in extremity	✓ Screen for iron deficiency for restless legs ✓ Acetaminophen (Tylenol®)
Jaw pain	✓ No measures (reassure patient that this would get better with time)
Flushing	✓ Reassurance

"I counsel patients using the analogy about cancer and chemotherapy: this [PAH] is a severe disease and a life-threatening disease. It costs something to get the disease under control." – Quote from a panelist on side effect management

- Panelists agreed that protocols that provide best practices for titration and dosing and guidance on monitoring patients on oral selexipag would be beneficial for oral selexipag expected side effect management.

Conclusions and key takeaways

- Selexipag is the only drug acting within the prostacyclin pathway indicated to delay disease progression and reduce PAH-related hospitalizations and is available as an oral twice-daily option.
- This Delphi panel provides expert consensus recommendations on the real-world usage of oral selexipag outside of a clinical trial, including additional granularity and insight on dosing, titration, and side effect management.
- Panelists noted that the maximum selexipag dose should be individualized for each patient to optimize treatment, including higher doses for patients with good tolerability.
- The titration of oral selexipag should be individualized depending on the characteristics of each patient, with panelists identifying different methods for slowing down titration to adapt for patients suffering from severe side effects or lacking tolerability.
- Panelists identified common side effects associated with oral selexipag, which are typically experienced 2–4 weeks after the first dose; however, it was highlighted that all these generally become manageable over time.
- Experts provided recommendations on methods for managing different oral selexipag side effects that can be included into guidelines. These may help improve clinical use and patients' experience, leading to improved adherence to therapy.

Acknowledgments

This study was funded by Johnson & Johnson. Editorial and poster design support were provided by Twist Medical and funded by Johnson & Johnson.

Disclosures

SW is a member of the speaker bureau for Johnson & Johnson, as well as a member of advisory boards for Johnson & Johnson, Merck, and Lixid. GD and PS are employees and shareholders of Johnson & Johnson. CB and MC are employees of Johnson & Johnson.

Pulmonary Hypertension



Scan the QR code

The QR code is intended to provide scientific information for individual reference, and the information should not be altered or reproduced in any way.

Follow the link:
<https://www.jnjmedicalconnect.com/media/attestation/congresses/pulmonary-hypertension/2025/capp/delphi-study-investigating-the-clinical-use-of-oral-selexipag-to-treat-pulmonary-arterial-hypertensi.pdf>

Presented at the Cardiology Advanced Practice Providers (CAPP) 2nd Annual National Conference;

Nashville, TN, USA; November 13–15, 2025

Previously presented at PHA 2024, Indianapolis, IN, USA, August 15–18, 2024; and the 2nd Annual APAPP National Conference, Nashville, TN, USA, June 26–28, 2025

REFERENCES:

- Janssen Submits New Drug Application (NDA) to U.S. FDA for UPRAVI® (selexipag) Injection for Intravenous Use to Treat Pulmonary Arterial Hypertension (PAH); 2020. Available at: <https://www.jnj.com/media-center/press-releases/janssen-submits-new-drug-application-nda-to-u-s-fda-for-upravi-selexipag-injection-for-intravenous-use-to-treat-pulmonary-arterial-hypertension-pah> (accessed May 27, 2025).
- Gaine S, et al. *Chest*. 2021;160(1):277–286. doi:10.1016/j.chest.2021.01.066.
- Panagiotidou E, et al. *Expert Opin Pharmacother*. 2021;22(1):29–36. doi:10.1080/14656566.2020.1812579.